CN112206254A - Preparation method of traditional Chinese medicine preparation for clearing heat, removing toxicity, resisting inflammation and diminishing swelling - Google Patents
Preparation method of traditional Chinese medicine preparation for clearing heat, removing toxicity, resisting inflammation and diminishing swelling Download PDFInfo
- Publication number
- CN112206254A CN112206254A CN202011336347.5A CN202011336347A CN112206254A CN 112206254 A CN112206254 A CN 112206254A CN 202011336347 A CN202011336347 A CN 202011336347A CN 112206254 A CN112206254 A CN 112206254A
- Authority
- CN
- China
- Prior art keywords
- water
- preparation
- time
- soaking
- decocting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title description 10
- 230000008961 swelling Effects 0.000 title description 7
- 231100000419 toxicity Toxicity 0.000 title description 5
- 230000001988 toxicity Effects 0.000 title description 5
- 206010061218 Inflammation Diseases 0.000 title description 4
- 230000004054 inflammatory process Effects 0.000 title description 4
- 230000003467 diminishing effect Effects 0.000 title description 2
- 239000002775 capsule Substances 0.000 claims abstract description 19
- 238000000227 grinding Methods 0.000 claims abstract description 17
- 238000005516 engineering process Methods 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 12
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 11
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 11
- 238000001694 spray drying Methods 0.000 claims abstract description 11
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 9
- 230000001741 anti-phlogistic effect Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 8
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 8
- 229960003321 baicalin Drugs 0.000 claims abstract description 8
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 claims abstract description 7
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 claims abstract description 7
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 claims abstract description 7
- 229930016920 cichoric acid Natural products 0.000 claims abstract description 7
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 claims abstract description 7
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- 241000245665 Taraxacum Species 0.000 claims description 7
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 241000437896 Corydalis bungeana Species 0.000 claims description 6
- 239000010231 banlangen Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 241000218176 Corydalis Species 0.000 claims description 5
- 239000000463 material Substances 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 11
- 230000002949 hemolytic effect Effects 0.000 description 8
- 241000194017 Streptococcus Species 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 6
- 241000334160 Isatis Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a method for preparing Pudilan antiphlogistic capsules by utilizing superfine grinding and spray drying technologies, which is characterized in that the grinding of part of medicinal materials of scutellaria baicalensis and the grinding of mixed extracts both adopt a dust-free superfine grinding technology, and the loss rate is controlled within 5 percent; the spray drying technology is adopted, so that the loss rate of the active ingredients of the obtained variety is low, the product yield is high, and the quality is stable. In the prepared Pudilan antiphlogistic capsule preparation, the baicalin content of each capsule is basically stabilized at 36.0mg +/-30%, and the chicoric acid content is stabilized at 0.80mg +/-40%.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a method for preparing Pudilan anti-inflammatory capsules by utilizing superfine grinding and spray drying technologies.
Background
The Pudilan antiphlogistic capsule is prepared with four kinds of Chinese medicinal materials including skullcap root, dandelion, corydalis tuber and isatis root. Has the effects of clearing away heat and toxic materials, relieving inflammation, and relieving swelling. Can be used for treating furuncle, pharyngitis, and tonsillitis. In the formula, the scutellaria baicalensis is bitter and cold in property and has the effects of clearing heat, drying dampness, purging intense heat, detoxifying and the like, and is a monarch drug; the dandelion is bitter, sweet and cold in property and taste, enters liver and stomach meridians, and has the effects of clearing away heat and toxic materials, relieving swelling, resolving masses, inducing diuresis and treating stranguria; the corydalis bungeana has pungent and bitter taste and cold property, has the functions of clearing away heat and toxic materials, cooling blood and relieving swelling, and is used for treating symptoms such as carbuncle, furuncle, wind-heat type common cold and the like; the isatis root is bitter in property and cold in taste, has the functions of clearing heat and removing toxicity, cooling blood and relieving sore throat, and is used for treating warm toxicity and macula, erysipelas, carbuncle and swelling and the like; dandelion, corydalis bungeana and isatis root are used as ministerial drugs. The medicines are combined to play the roles of clearing heat and removing toxicity, and resisting inflammation and reducing swelling.
The preparation process of the Chinese patent medicine generally has the problems of extensive preparation process and large quality difference among product batches, so the establishment of the quality standard also mainly controls the minimum content of main active ingredients.
As a brand new technical means, a great deal of research results show that after the traditional Chinese medicinal materials are subjected to superfine grinding, the dosage of the traditional Chinese medicinal superfine decoction pieces can be reduced to 1/3-1/2 of the clinical dosage of the traditional Chinese medicinal decoction pieces, and the pharmacological action of the traditional Chinese medicinal superfine decoction pieces can be basically kept unchanged. This may be due to the increased dissolution of the active ingredient and the more absorption of the fine powder particles by the gastrointestinal tract. Due to the improvement of science and technology and the innovation of engineering equipment technology, dust-free superfine grinding is possible, the loss of medicinal materials can be greatly reduced by the dust-free superfine grinding, and the possibility of environmental pollution can also be greatly reduced. The invention adopts the spray drying technology, can greatly improve the drying efficiency, improve the loss rate of the effective components of the dried product and improve the product quality. The prepared Pudilan antiphlogistic capsule preparation has small batch-to-batch quality difference, and each finished product contains baicalin with the content basically stabilized at 36.0mg +/-30 percent and chicoric acid with the content stabilized at 0.80mg +/-40 percent.
Disclosure of Invention
The invention aims to provide a superfine powder traditional Chinese medicine composition for promoting blood circulation, removing blood stasis, stimulating the menstrual flow and eliminating symptoms from the perspective of improving the drug effect by superfine grinding; meanwhile, a preparation method of the traditional Chinese medicine composition is provided.
The invention is realized by the following technical scheme:
a preparation method of Pudilan antiphlogistic capsule is characterized in that the prescription is 3 parts of radix scutellariae, 8 parts of dandelion, 2 parts of corydalis bungeana and 3 parts of radix isatidis; the preparation method comprises the following steps:
(1) 0.55 part of scutellaria baicalensis, and carrying out dust-free superfine grinding to the fineness of 50-100 mu m for later use;
(2) extracting the rest Scutellariae radix with 60% ethanol for 2 times, 10 times the amount of the first time for 3 hr, 10 times the amount of the second time for 2 hr, filtering, mixing filtrates, and recovering ethanol under reduced pressure to obtain soft extract with relative density of 1.15-1.30 (80 deg.C);
(3) decocting herba Taraxaci and herba corydalis Bungeanae in water for 2 times, decocting for 1 hr with 10 times of water for the first time, decocting for 1 hr with 8 times of water for the second time, filtering, and mixing filtrates;
(4) adding water into radix Isatidis, soaking at 90 deg.C for 2 times, soaking with 10 times of water for 1 hr for the first time, soaking with 8 times of water for 1 hr for the second time, filtering, mixing filtrates, adding the water extractive solution of step (3), and concentrating under reduced pressure to obtain soft extract with relative density of 1.15-1.30 (80 deg.C);
(5) and (4) adding the thick paste obtained in the step (2) into the concentrated paste of the alcohol extract, spray-drying, adding the scutellaria baicalensis ultra-fine powder obtained in the step (1), uniformly mixing and subpackaging.
The preparation method is characterized in that the superfine grinding in the step (1) and the step (5) adopts a dust-free superfine grinding technology, and the loss rate is within 5 percent.
The preparation method is characterized in that the spray drying technology adopted in the step (5) has the following process parameters: the air inlet temperature is 130 ℃, the air outlet temperature is 65 ℃, and the rotating speed of the atomizer is 2000-2500 rpm.
The preparation method is characterized in that in the prepared Pudilan antiphlogistic capsule preparation, the baicalin content of each capsule is basically stabilized at 36.0mg +/-30%, and the chicoric acid content is stabilized at 0.80mg +/-40%.
The invention has the beneficial effects that: the dust-free superfine grinding technology and the spray drying technology are adopted, so that the yield of the active ingredients can be greatly improved, and the product quality is improved. The prepared Pudilan antiphlogistic capsule preparation has the characteristics of low loss rate of effective components, high product yield and stable quality, wherein each capsule of the finished product contains baicalin basically stabilized at 36.0mg +/-30%, and the content of chicoric acid is stabilized at 0.80mg +/-40%.
The specific implementation mode is as follows:
example 1
271g of scutellaria baicalensis, 722g of dandelion
Corydalis Bungeana 180g isatis root 271g
(1) 150.5 g of scutellaria baicalensis, and carrying out dust-free ultrafine grinding to the fineness of 50-100 mu m for later use;
(2) extracting the rest Scutellariae radix with 60% ethanol for 2 times, 10 times the amount of the first time for 3 hr, 10 times the amount of the second time for 2 hr, filtering, mixing filtrates, and recovering ethanol under reduced pressure to obtain soft extract with relative density of 1.20-1.30 (80 deg.C);
(3) decocting herba Taraxaci and herba corydalis Bungeanae in water for 2 times, decocting for 1 hr with 10 times of water for the first time, decocting for 1 hr with 8 times of water for the second time, filtering, and mixing filtrates;
(4) adding water into radix Isatidis, soaking at 90 deg.C for 2 times, soaking with 10 times of water for 1 hr for the first time, soaking with 8 times of water for 1 hr for the second time, filtering, mixing filtrates, adding the water extractive solution of step (3), and concentrating under reduced pressure to obtain soft extract with relative density of 1.20-1.30 (80 deg.C);
(5) and (4) adding the thick paste obtained in the step (2) into the alcohol extract concentrated paste obtained in the step (2), performing spray drying, adding the scutellaria baicalensis ultra-fine powder obtained in the step (1), uniformly mixing, performing dust-free ultra-fine grinding to obtain the powder with the fineness of 50-100 mu m, uniformly mixing, subpackaging and granulating. Lot number 20190401.
Example 2
271g of scutellaria baicalensis, 722g of dandelion
Corydalis Bungeana 180g isatis root 271g
(1) 150.5 g of scutellaria baicalensis, and carrying out dust-free superfine grinding to the fineness of 10-15 mu m for later use;
(2) extracting the rest Scutellariae radix with 60% ethanol for 2 times, 10 times for 3 hr, 8 times for 2 hr, filtering, mixing filtrates, and recovering ethanol under reduced pressure to obtain soft extract with relative density of 1.20-1.30 (80 deg.C);
(3) decocting herba Taraxaci and herba corydalis Bungeanae in water for 2 times, decocting for 1 hr with 10 times of water for the first time, decocting for 1 hr with 8 times of water for the second time, filtering, and mixing filtrates;
(4) adding water into radix Isatidis, soaking at 90 deg.C for 2 times, soaking with 10 times of water for 1 hr for the first time, soaking with 8 times of water for 1 hr for the second time, filtering, mixing filtrates, adding the water extractive solution of step (3), and concentrating under reduced pressure to obtain soft extract with relative density of 1.20-1.30 (80 deg.C);
(5) and (4) adding the thick paste obtained in the step (2) into the thick paste obtained in the step (4), spray-drying, adding the thick paste into the thick paste obtained in the step (1), and uniformly mixing and subpackaging the mixture. Lot number 20190402.
Batches 20190801, 20190802, 20190803, 20190804, 20190805, 20190901, 20190902, 20190903, 20190904 and 20190905 were prepared in the same manner.
The baicalin content of the ten batches of samples is measured according to a content measuring method of a quality standard, and the result is as follows: the baicalin content of each granule in the final product is stabilized at 36.0mg + -30%, and the chicoric acid content is stabilized at 0.80mg + -40%.
| Batch number | Baicalin content | Chicoric acid content |
| 20190801 | 26.1 mg/granule | 0.50 mg/granule |
| 20190802 | 29.2 mg/granule | 0.55 mg/granule |
| 20190803 | 37.5 mg/granule | 0.76 mg/granule |
| 20190804 | 42.5 mg/granule | 0.82 mg/granule |
| 20190805 | 40.7 mg/granule | 0.64 mg/granule |
| 20190901 | 35.7 mg/granule | 0.95 mg/granule |
| 20190902 | 43.8 mg/granule | 0.86 mg/granule |
| 20190903 | 32.6 mg/granule | 0.78 mg/granule |
| 20190904 | 39.5 mg/granule | 0.82 mg/granule |
| 20190905 | 38.7 mg/granule | 0.77 mg/granule |
Animal experimental data
Acute tonsillitis is nonspecific acute inflammation of palatine tonsil, and is an acute systemic disease accompanied with systemic symptoms. Hemolytic streptococcus, in particular type B hemolytic streptococcus, staphylococcus aureus are the most common pathogenic bacteria.
Material
1.1 test drugs and reagent pudilan anti-inflammatory capsules, provided by the company, batch number: 201901, preparing into suspension with required concentration with distilled water before use; penicillin sodium, batch number: 180702, produced by Dalian pharmaceutical factory; gentamicin injection, suzhou product of the sixth pharmaceutical factory, lot number: 1800905, respectively; ibuprofen, content 99.97%, batch number: 180605, products of the Shandong Xinhua pharmaceutical factory; aspirin, lot number: 180903, manufactured by Jilin pharmaceutical factories. All strains are separated from clinical specimens and identified by a microbiological research laboratory of university of Bai Qien medical science; the pertussis vaccine, diphtheria and tetanus toxoid mixed preparation is a product of research institute of biological products of catharanthus roseus, and the batch number is as follows: 180103.
18-20 g of Kunming mouse, 150-170 g of Wister rat and 2-2.5 kg of big-ear white rabbit, which are all laboratory animal feeding rooms of the company.
Method and results
2.1 in vitro bacteriostasis sterilization test tubes 96 are divided into 8 groups, 2ml of serum broth culture medium containing 10% of serum is added into the groups 1 and 2, 2ml of common broth culture medium is added into the groups 3-8 respectively, 2m1 of Pudilan antiphlogistic capsule (128%) dissolved by the respective culture medium is added into the first tube of each group, the tubes are sequentially diluted to the 9 th tube in multiple proportion, the 10 th tube is a control tube (without medicine), and the 11 th tube and the 12 th tube are respectively added with human penicillin sodium and gentamicin to ensure that the final concentration is 50 mu g/ml. Respectively inoculating each loop of 8 bacterial suspensions of newly-propagated and activated bacteria into 8 groups of test tubes, carrying out shaking culture at 37 ℃ for 48 hours, taking out observation results, obtaining clear appearance without turbidity to indicate no bacterial growth, respectively scribing cultures with three adjacent concentrations above and below the serum agar or common agar plates, placing the plates on the plates at 37 ℃ for 48 hours, and taking less than 3 bacterial colonies on each plate culture medium as the standard for determining MIC (minimal inhibitory concentration), wherein the results are shown in Table 1.
TABLE 1 Pudilan anti-inflammatory Capsule results of bacteriostasis test
The result shows that the MICs of the Pudilan anti-inflammatory capsule on alpha hemolytic streptococcus, beta hemolytic streptococcus, staphylococcus citreus, staphylococcus epidermidis, staphylococcus aureus, pseudomonas aeruginosa, proteus and escherichia coli are respectively 40, 20, 80, 320, 640 and 640 mg/kg.
Therapeutic effects on staphylococcus aureus and beta hemolytic streptococcus-infected mice 180 mice were randomly divided into 10 groups, administered 6 days before infection and 1 hour daily for 1 time, totally 7 times, 1 hundred million/one staphylococcus aureus was intravenously infected or 3 hundred million hemolytic streptococcus were intraperitoneally injected in each group 1 hour after the last administration, and the results of observing the mortality of the mice within 48 hours are shown in table 2.
TABLE 2 treatment of mice infected with Staphylococcus aureus and beta hemolytic streptococcus with Pudilan anti-inflammatory Capsule
The result shows that 14 g/kg and 7 g/kg of Pudilan anti-inflammatory capsule have obvious protective effect on mice infected by staphylococcus aureus and beta hemolytic streptococcus.
Claims (4)
1. A preparation method of Pudilan antiphlogistic capsule is characterized in that the prescription is 3 parts of radix scutellariae, 8 parts of dandelion, 2 parts of corydalis bungeana and 3 parts of radix isatidis; the preparation method comprises the following steps:
(1) 0.55 part of scutellaria baicalensis, and carrying out dust-free superfine grinding to the fineness of 50-100 mu m for later use;
(2) extracting the rest Scutellariae radix with 60% ethanol for 2 times, 10 times the amount of the first time for 3 hr, 10 times the amount of the second time for 2 hr, filtering, mixing filtrates, recovering ethanol under reduced pressure, and concentrating to obtain soft extract with relative density of 1.15-1.30 (80 deg.C);
(3) decocting herba Taraxaci and herba corydalis Bungeanae in water for 2 times, decocting for 1 hr with 10 times of water for the first time, decocting for 1 hr with 8 times of water for the second time, filtering, and mixing filtrates;
(4) adding water into radix Isatidis, soaking at 90 deg.C for 2 times, soaking with 10 times of water for 1 hr for the first time, soaking with 8 times of water for 1 hr for the second time, filtering,
mixing filtrates, adding the water extractive solution of step (3), and concentrating under reduced pressure to obtain soft extract with relative density of 1.15-1.30 (80 deg.C);
(5) and (4) adding the thick paste obtained in the step (2) into the concentrated paste of the alcohol extract, spray-drying, adding the scutellaria baicalensis ultra-fine powder obtained in the step (1), uniformly mixing and subpackaging.
2. The process according to claim 1, wherein the micronization in step (1) and step (5) is carried out by a dust-free micronization technique with a loss of less than 5%.
3. The preparation method of claim 1, wherein the spray drying technology adopted in the step (5) comprises the following process parameters: the air inlet temperature is 130 ℃, the air outlet temperature is 65, and the rotating speed of the atomizer is 2000-2500 rpm.
4. The method of claim 1, wherein the Pudilan anti-inflammatory capsule preparation is prepared to have a baicalin content stabilized substantially at 36.0mg + -30% and a chicoric acid content stabilized at 0.80mg + -40%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011336347.5A CN112206254A (en) | 2020-11-25 | 2020-11-25 | Preparation method of traditional Chinese medicine preparation for clearing heat, removing toxicity, resisting inflammation and diminishing swelling |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011336347.5A CN112206254A (en) | 2020-11-25 | 2020-11-25 | Preparation method of traditional Chinese medicine preparation for clearing heat, removing toxicity, resisting inflammation and diminishing swelling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112206254A true CN112206254A (en) | 2021-01-12 |
Family
ID=74068047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011336347.5A Pending CN112206254A (en) | 2020-11-25 | 2020-11-25 | Preparation method of traditional Chinese medicine preparation for clearing heat, removing toxicity, resisting inflammation and diminishing swelling |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112206254A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117617500A (en) * | 2023-12-27 | 2024-03-01 | 南京玉鹤鸣医学营养科技股份有限公司 | Functional formula powder suitable for postoperative recovery and preparation method and application method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940303A (en) * | 2015-06-26 | 2015-09-30 | 江苏颐海药业有限责任公司 | Method for preparing pudilan anti-inflammation capsules |
| CN109718278A (en) * | 2017-10-27 | 2019-05-07 | 江苏颐海药业有限责任公司 | A method of Pudilan antiphlogistic capsule is prepared using microwave crushing |
-
2020
- 2020-11-25 CN CN202011336347.5A patent/CN112206254A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940303A (en) * | 2015-06-26 | 2015-09-30 | 江苏颐海药业有限责任公司 | Method for preparing pudilan anti-inflammation capsules |
| CN109718278A (en) * | 2017-10-27 | 2019-05-07 | 江苏颐海药业有限责任公司 | A method of Pudilan antiphlogistic capsule is prepared using microwave crushing |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117617500A (en) * | 2023-12-27 | 2024-03-01 | 南京玉鹤鸣医学营养科技股份有限公司 | Functional formula powder suitable for postoperative recovery and preparation method and application method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114053343B (en) | Traditional Chinese medicine composition, preparation method and application | |
| CN108686045B (en) | Callicarpa nudiflora composition and application thereof in treating pharyngitis | |
| CN112587595A (en) | Traditional Chinese medicine composition for clearing heat and relieving exterior syndrome and preparation method thereof | |
| CN111053803B (en) | Composition with anti-staphylococcus aureus effect and preparation method and application thereof | |
| CN111407817A (en) | Traditional Chinese medicine composition for preventing respiratory tract infection pathogenic microorganisms and preparation method thereof | |
| CN101120950A (en) | Application of realgar microorganism extracting liquid in preparing anti-tumor medicine | |
| CN108524685B (en) | Composition for treating children herpangina and application thereof | |
| CN112206254A (en) | Preparation method of traditional Chinese medicine preparation for clearing heat, removing toxicity, resisting inflammation and diminishing swelling | |
| CN117379480A (en) | Compound traditional Chinese medicine granule for inhibiting drug-resistant pathogenic bacteria and preparation method and application thereof | |
| CN103301271B (en) | Tibetan medicine for treating pharyngitis and preparation method thereof | |
| CN1723965A (en) | Method and use for preparing medicine extracted myrobalan for treating diseases infected by bacteria or virus | |
| CN108403858B (en) | Callicarpa nudiflora extract composition for treating hand-foot-and-mouth disease and application thereof | |
| CN113350440A (en) | Application of traditional Chinese medicine composition in preparation of antibacterial drugs | |
| CN104971088A (en) | Tibetan artemisia capillaris extract and preparation method, drug composition and application thereof | |
| CN102068464B (en) | Antibacterial and antiviral effective part extract of medicated leaven and medicinal use thereof | |
| CN101084951B (en) | Medicine for treating diseases concerned with respiratory and preparation method and application thereof | |
| CN108785383B (en) | Antibacterial gynecological external medicine composition and preparation method and application thereof | |
| CN109200233B (en) | Medicine for treating bacterial diseases of lumbricus and preparation method thereof | |
| CN109316533B (en) | Fermented traditional Chinese medicine compound preparation for removing endotoxin in pig body and application thereof | |
| CN101554405A (en) | Selfheal, mulberry leaf and wild chrysanthemum dripping pills and preparation method thereof | |
| CN109381607A (en) | A kind of pharmaceutical composition and its preparation process treated blood disease and merge bacterium infection | |
| WO2007059649A1 (en) | Chinese pharmaceutical compositions for treating upper respiratory tract infection and processes for preparation thereof | |
| CN116036174B (en) | Medicine for treating pulmonary nodules and preparation method thereof | |
| CN109172649A (en) | A kind of application of Chinese medicine composition in the drug that preparation prevents and treats Streptococcus suis | |
| CN115364169B (en) | Chinese medicinal composition for resisting helicobacter pylori, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210112 |